Appendix: Estimating utility values for non-alcoholic steatohepatitis health states: a discrete choice experiment

These are peer-reviewed supplementary appendices and figures for the article 'Estimating utility values for non-alcoholic steatohepatitis health states: a discrete choice experiment' published in the Journal of Comparative Effectiveness Research.Appendix file 1: General Public DCE SurveyAppendix file 2: Sample DCE choice questionsAppendix File 3: Estimated marginal utilities among NASH patients by fibrosis stage based on results from conditional logit modelAppendix File 4: NASH Check scores and frequency of symptoms by NASH Fibrosis StageAppendix File 5: Linear regression results exploring associations between background and clinical characteristics with EQ-5D utility values in the patient sample (n=154)Background: This study estimated utility values for non-alcoholic steatohepatitis (NASH). Previous studies have assumed that health-related quality of life does not vary between the early stages of NASH. Materials & Methods: Discrete choice experiment (DCE) surveys estimated the value of avoiding fibrosis progression. Patients also completed the EQ-5D-5L. Marginal rates of substitution estimated utility change associated with fibrosis progression. Results: DCE surveys were completed by the UK general public (n = 520) and patients with NASH (n = 154). The utility decline between fibrosis stages F1 and F4 decompensated was between -0.521 to -0.646 (depending on method). Conclusion: Three methods were used to estimate utilities for NASH, each one showed sensitivity to advancing fibrosis, including in the early stages, which is often considered asymptomatic.

本数据集包含对发表于《比较疗效研究杂志》上的文章《评估非酒精性脂肪性肝炎（NASH）健康状况的效用值：一项离散选择实验》的同行评审补充附录和图表。附录文件1：一般公众离散选择实验调查；附录文件2：样本离散选择选择问题；附录文件3：基于条件逻辑回归模型结果的NASH患者按纤维化阶段估计的边际效用；附录文件4：NASH纤维化阶段检查评分及症状频率；附录文件5：线性回归结果，探讨背景和临床特征与患者样本（n=154）中EQ-5D效用值之间的关联。研究背景：本研究旨在估计非酒精性脂肪性肝炎（NASH）的效用值。先前研究假设NASH早期阶段的健康状况相关生活质量没有变化。研究材料与方法：离散选择实验（DCE）调查估计了避免纤维化进展的价值。患者还完成了EQ-5D-5L问卷。边际替代率估计了与纤维化进展相关的效用变化。研究结果：DCE调查由英国公众（n=520）和NASH患者（n=154）完成。纤维化阶段F1至F4进展至失代偿期的效用下降介于-0.521至-0.646之间（取决于方法）。研究结论：采用三种方法估计NASH的效用值，每种方法均显示出对纤维化进展的敏感性，包括早期阶段，而这些阶段通常被认为是无症状的。